Ewing sarcoma maintenance therapy
In Ewing sarcoma (ES), multimodal therapy of surgery, radiation, and chemotherapy is successful in 70% of patients with localized disease. The cure rate for patients with metastatic disease drops to 20-40%, and is even lower for recurrent/refractory disease. In ES, the 20 year cumulative incidence of recurrence is as high as 13%. One mechanism of recurrence is the reactivation of dormant cancer cells. It is the goal of this project to identify drugs that prevent the regrowth of cancer cells that give rise to recurrent disease.
Maintenance Therapy Assay
The goal is to stress ES cell cultures with chemotherapy to recapitulate conventional therapy. Most of the cells (90-95%) will be sensitive to the therapy, but the surviving cells will be assayed for sensitivity to maintenance therapy drug candidates.
Experiments to consistently demonstrate 95% chemotherapy-induced cell killing are ongoing. Preliminary experiments with 10 maintenance drug candidates have been completed. Initial maintenance therapy assay is imminent.